Literature DB >> 2559852

The effect of cytomegalovirus infection on the adherence of polymorphonuclear leucocytes to endothelial cells.

A H Span1, C P Van Boven, C A Bruggeman.   

Abstract

Adherence of polymorphonuclear leucocytes (PMN) to the endothelial lining of blood vessels is an essential component of the inflammatory response. In this study the effect of cytomegalovirus (CMV) infection on the adherence of PMNs has been examined using an in vitro model system. Human umbilical venous endothelial cells (HUVEC) were grown on fibronectin-coated plastics. CMV infection of HUVEC resulted in the appearance of viral antigens in a small percentage of the cells. At 24 h post-infection when no virus-induced cytopathic effect could be observed in the cell monolayers, the adherence of PMNs was significantly increased. The virus-induced adherence effect was cell bound and could not be induced by soluble components in the medium of the virus-infected cells. The augmentation of the PMN adherence to CMV-infected endothelium was sensitive to tunicamycin suggesting that the virus infection induces the expression of glycoproteins on the HUVEC membranes which are responsible for the PMN adherence. Thus CMV infection of the endothelium results in an increased adherence of PMNs. In the in vivo situation systemic viral infection can potentially lead to infection of blood vessel endothelium and thus can induce a damage of endothelium. This phenomenon could play a role in the atherogenesis process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559852     DOI: 10.1111/j.1365-2362.1989.tb00272.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

Review 1.  Microorganisms in the aetiology of atherosclerosis.

Authors:  S A Morré; W Stooker; W K Lagrand; A J van den Brule; H W Niessen
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

2.  Cytomegalovirus induced PMN adherence in relation to an ELAM-1 antigen present on infected endothelial cell monolayers.

Authors:  A H Span; W Mullers; A M Miltenburg; C A Bruggeman
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

3.  Increased adherence of CD2 peripheral blood lymphocytes to cytomegalovirus-infected fibroblasts is blocked by anti-LFA-3 antibody.

Authors:  J E Grundy; G S Pahal; A N Akbar
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

4.  Humoral immunity to cytomegalovirus and chronic graft-versus-host disease.

Authors:  Aryan M Namboodiri; Paul J Nietert; Persis P Wadia; David B Miklos; Janardan P Pandey
Journal:  Viral Immunol       Date:  2012-07-17       Impact factor: 2.257

Review 5.  Modulation of major histocompatibility complex antigen expression by viral infection.

Authors:  C R Rinaldo
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

Review 6.  Resistant pathogens, fungi, and viruses.

Authors:  Christopher A Guidry; Sara A Mansfield; Robert G Sawyer; Charles H Cook
Journal:  Surg Clin North Am       Date:  2014-10-03       Impact factor: 2.741

7.  Human cytomegalovirus induces a biphasic inflammatory response in primary endothelial cells.

Authors:  H C Jeffery; C Söderberg-Naucler; L M Butler
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

8.  In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia.

Authors:  M G Revello; E Percivalle; E Arbustini; R Pardi; S Sozzani; G Gerna
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

9.  Membrane related effects in endothelial cells induced by human cytomegalovirus.

Authors:  A G van Geelen; M E Slobbe-van Drunen; A D Muller; C A Bruggeman; M C Van Dam-Mieras
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

10.  Translational informatics approach for identifying the functional molecular communicators linking coronary artery disease, infection and inflammation.

Authors:  Ankit Sharma; Madankumar Ghatge; Lakshmi Mundkur; Rajani Kanth Vangala
Journal:  Mol Med Rep       Date:  2016-03-18       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.